BUY Cipla Ltd. — Elara Capital
byElara CapitalHorizon: NA (inferred 1 year)28 Oct 2026via ET Now (Live)
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Cipla Q2 Results Review: ICICI Securities Remains Bullish After Inline Numbers; Check Target Price
NewsNdtv-Profit·28 Oct · today
Cipla’s US recovery, biosimilar pipeline key to future growth prospects
NewsEt-Markets·28 Oct · today
Dr Reddy's stock could rise 10-15% if a major biosimilar gets approved in December: Systematix
NewsCnbc-Tv18·27 Oct · yesterday
8 other SEBI-registered advisors have active long-term BUY calls on this stock
Advisor consensus · same horizon·28 Sept · 1mo ago
Cipla Q2 Results: US sales meet expectations, margins narrow from last year
NewsCnbc-Tv18·27 Oct · yesterday
Cipla Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
NSE · Outcome of Board Meeting·27 Oct · yesterday
These four pharma stocks will be reacting to important news updates today
NewsCnbc-Tv18·5 Oct · 3w ago
Long-term trend bearish — 200-day average falling over the past quarter
Technicals · trend·28 Oct · today
3 other SEBI-registered advisors have active long-term SELL calls on this stock, with 1 issued in the last 14 days
Advisor consensus · same horizon·28 Oct · today
Cipla Eyes Margin Rebound From FY28 As Middle East Freight Squeeze Hits Q2 Costs
NewsNdtv-Profit·27 Oct · yesterday
Cipla Q2 net profit falls 35% to Rs 878 crore, revenue dips 2%
NewsEt-Markets·27 Oct · yesterday
Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore; revenue slips 2%
NewsEt-Markets·27 Oct · yesterday
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Cipla
- SELL — Morgan Stanley28 Oct 2026 · ~1 year · target ₹1,214 · Active
- BUY — IDBI Capital26 Oct 2026 · ~2 weeks · target ₹1,403 · SL hit
- BUY — Prakash Gaba26 Oct 2026 · Same day · target ₹1,350 · Target hit
- BUY — Manas Jaiswal26 Oct 2026 · Same day · target ₹1,360 · Expired
- BUY — Ashish Bahety, Profitmart Securities29 Sept 2026 · Same day · target ₹1,420 · Expired
More from Elara Capital
- BUY Jio Platforms28 Oct 2026 · ~1 year · target ₹1,367 · Target hit
- BUY Sona BLW Precision Forgings28 Oct 2026 · ~1 year · target ₹960 · Active
- BUY Maruti Suzuki India28 Oct 2026 · ~1 year · target ₹15,378 · Active
- BUY UTI Asset Management Company28 Oct 2026 · ~1 year · target ₹960 · Active
- BUY Sumitomo Chemical India28 Oct 2026 · ~1 year · target ₹524 · Active

